Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study

Bone Marrow Transplantation
L H CoutinhoN G Testa

Abstract

Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine chronic phase CML patients, ineligible for HLA-matched sibling donor transplant, and who were selected on the basis of a pre-transplant screening LTC test. Of the transplanted patients three died; two of graft failure and one of therapy-related toxicity with 97% Ph- cells 16 months following the autograft. The reconstituting haemopoietic cells in the seven engrafted patients were 100% Ph- in four, > or = 90% Ph- in two and 71% Ph- in the seventh, with a duration of complete cytogenetic response of 6-12 months. Three patients reverted to chronic phase and 100% Ph+ haemopoiesis 27-36 months post-autograft. The other three patients remain in continuous haematological remission with 22% Ph- cells in one and complete cytogenetic remission in the other two 3-4 years post-autograft. IFN therapy was generally introduced on the first evidence of recurrence of Ph+ cells or of cytogenetic deterioration. Further strategies to mo...Continue Reading

Citations

Mar 19, 2002·Journal of Inorganic Biochemistry·A DaiberV Ullrich
May 30, 2001·Experimental Hematology·A E FrimbergerP J Quesenberry
Apr 26, 2002·British Journal of Haematology·John D GraingerRichard F Stevens
Jul 24, 2004·Hematology/oncology Clinics of North America·Ravi Bhatia, Philip B McGlave
Mar 31, 2000·Blood Reviews·R ChopraA G Elefanty
Jun 13, 2001·Oncogene·W M TooneN Jones
Oct 19, 2001·Oncogene·A Y TsygankovG Swaminathan
Jan 29, 2019·Pediatric Blood & Cancer·Stefano ParodiAnnalisa Pezzolo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.